Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare autoimmune diseases that affect the central nervous system, particularly the optic nerves and spinal cord. NMOSD is characterized by recurrent attacks of inflammation that can cause severe damage to the nerves and lead to permanent disability. The severity and frequency of NMOSD attacks can vary widely between individuals, and the disease can be difficult to diagnose due to its rarity and similarity to other neurological conditions. The NMOSD in China market size is projected to grow by USD 169.6 million from 2023 to 2029, registering a CAGR of 23.47 percent, according to the latest market data.

This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on NMOSD can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.

The leading players in the NMOSD market include Bio-Thera Solutions Ltd., HBM Holdings Limited, Roche Holding AG, Rongchang Pharmacy Co. Ltd., Tianjin Accendatech Technology Co. Ltd.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
▹ Get a detailed picture of the China Neuromyelitis Optica Spectrum Disorders Market
▹ Identify segments/areas to invest in over the forecast period in the China Neuromyelitis Optica Spectrum Disorders Market
▹ Understand the competitive environment, the market’s leading players
▹ The market estimate for ease of analysis across scenarios in Excel format.
▹ Strategy consulting and research support for three months.
▹ Print authentication provided for the single-user license.